Survodutide vs tirzepatide: tirzepatide has produced more weight loss in its trials, about 21% at the top dose over 72 weeks, than survodutide’s 12% to 13% over 76 weeks, though the two have never been tested head to head.[5][1] Survodutide’s main strength is the liver: it uses glucagon to act directly on liver fat and has FDA Breakthrough Therapy designation for MASH.[3][10] Tirzepatide is FDA-approved as Zepbound and Mounjaro; survodutide is not approved anywhere.[8][9]
For the research on each, see our survodutide profile and tirzepatide profile. Other glucagon-pathway drugs include mazdutide, pemvidutide and the triple agonist retatrutide. The GLP-1 drugs hub covers the whole field.
At a glance
| Survodutide | Tirzepatide | |
|---|---|---|
| Maker | Boehringer Ingelheim (from Zealand Pharma)[3] | Eli Lilly[8] |
| Receptors | GLP-1 + glucagon[1] | GLP-1 + GIP[8] |
| Dosing | Weekly injection, 3.6 or 6.0 mg in phase 3[1] | Weekly injection, 2.5 to 15 mg[8] |
| Weight loss, no diabetes | −12.2% to −13.0% (76 weeks)[1] | −15.0% to −20.9% (72 weeks)[5] |
| Weight loss, type 2 diabetes | −8.2% to −9.8% (76 weeks)[2] | −12.8% to −14.7% (72 weeks)[6] |
| Liver data | Phase 3 liver-fat trial; phase 2 biopsy trial[3][4] | Phase 2 biopsy trial[7] |
| Status | Investigational; Breakthrough Therapy for MASH[10] | Approved: weight, sleep apnea, type 2 diabetes[8][9] |
How they work
Both drugs activate the GLP-1 receptor, which curbs appetite and slows stomach emptying. The difference is the second target:
- Survodutide also activates the glucagon receptor. Glucagon acts directly on the liver and raises energy use, which may help burn liver fat.[3] In a reanalysis of its phase 2 liver trial, weight loss explained only about 36% of the improvement in liver scarring, suggesting a direct liver effect.[13]
- Tirzepatide also activates the GIP receptor, another gut hormone involved in insulin release and fat metabolism.[8]
Put simply, tirzepatide’s design has so far delivered more total weight loss, while survodutide’s glucagon arm is aimed at the liver. That is why the two drugs tend to be discussed for slightly different patients: tirzepatide for weight, blood sugar and sleep apnea, and survodutide, if approved, possibly for people whose main problem is fatty liver disease with scarring.
Weight loss results
| Trial | Drug | Who | Weeks | Weight change | Placebo |
|---|---|---|---|---|---|
| SYNCHRONIZE-1 | Survodutide 3.6 / 6.0 mg | 725 without diabetes | 76 | −12.2% / −13.0% | −5.4%[1] |
| SURMOUNT-1 | Tirzepatide 5 / 10 / 15 mg | 2,539 without diabetes | 72 | −15.0% / −19.5% / −20.9% | −3.1%[5] |
| SYNCHRONIZE-2 | Survodutide 3.6 / 6.0 mg | 752 with type 2 diabetes | 76 | −8.2% / −9.8% | −3.9%[2] |
| SURMOUNT-2 | Tirzepatide 10 / 15 mg | 938 with type 2 diabetes | 72 | −12.8% / −14.7% | −3.2%[6] |
Boehringer’s analysis of people who stayed on treatment in SYNCHRONIZE-1 reported up to 16.6% weight loss.[14] SYNCHRONIZE-1 also had an unusually large placebo response (−5.4%), which narrows the gap with placebo.[1]
Survodutide’s earlier phase 2 obesity trial looked closer to tirzepatide: weight fell up to 14.9% at the 4.8 mg dose over 46 weeks, versus 2.8% on placebo. But only about 61% of people on survodutide completed treatment, and three-quarters had stomach side effects.[15] The phase 3 program used slower dose increases, and its results came in lower. Tirzepatide’s results, by contrast, have held up across its phase 3 trials, including in people with type 2 diabetes.[5][6]
Fatty liver (MASH) results
MASH is fatty liver disease with inflammation, which can scar the liver.
| Trial | Drug | Result | Placebo |
|---|---|---|---|
| Phase 2 biopsy trial, 48 weeks (293 people) | Survodutide | MASH improved without worse fibrosis in up to 62% | 14%[4] |
| SYNCHRONIZE-MASLD, 48 weeks (216 people) | Survodutide 6.0 mg | Liver fat cut by 30% or more in 68.5% | 28.6%[3] |
| SYNERGY-NASH, 52 weeks (190 people) | Tirzepatide | MASH resolved without worse fibrosis in 44% to 62% | 10%[7] |
The definitions differ (“improvement” vs “resolution”), so these numbers can’t be compared directly. Neither drug is approved for MASH. Survodutide’s larger phase 3 biopsy trial, LIVERAGE, is under way.[11]
Scarring (fibrosis) matters most for long-term liver health. In the phase 2 trials, fibrosis improved by at least one stage in 34% to 36% of people on survodutide versus 22% on placebo, and in 51% to 55% on tirzepatide versus 30% on placebo.[4][7] These were small, one-year trials, so neither result proves fewer cases of cirrhosis or liver failure.
Side effects and safety
- Survodutide: gastrointestinal side effects affected 80.9% to 89.7% in SYNCHRONIZE-1, versus 47.9% on placebo, and 72.8% to 77.7% in SYNCHRONIZE-2, versus 38.6%.[1][2] In the phase 2 liver trial, nausea affected 66% and vomiting 41%.[4]
- Tirzepatide: side effects are also mainly gastrointestinal and mostly mild to moderate, occurring mainly during dose increases; 4.3% to 7.1% stopped because of side effects in SURMOUNT-1, versus 2.6% on placebo.[5]
- Labels: Zepbound and Mounjaro carry a boxed warning about thyroid C-cell tumors in rodents.[8][9] Survodutide has no label yet; its heart safety is being studied in SYNCHRONIZE-CVOT.[12]
In practice, both drugs start at a low dose that is raised slowly to limit nausea. Survodutide’s trials still saw many people stop because of stomach effects, so tolerability may be its biggest hurdle. Neither drug should be combined with another GLP-1 medicine.[8]
Legal status, cost and access
| Survodutide | Tirzepatide | |
|---|---|---|
| FDA status | Not approved; Breakthrough Therapy (MASH)[10] | Zepbound (weight, sleep apnea), Mounjaro (type 2 diabetes)[8][9] |
| Self-pay price | None | Zepbound $299 to $449 a month via LillyDirect[16] |
| Compounding | Not on FDA’s lists of substances pharmacies may use[17] | FDA declared the shortage over, which limits compounded copies[18] |
For more on tirzepatide prices, see tirzepatide cost. Products sold online as “survodutide” are unapproved research chemicals with no quality oversight.
As of October 2026 we found no announcement that Boehringer Ingelheim had filed survodutide with FDA for obesity, so no approval date can be predicted. Until then, the approved options are the ones in our 2026 comparison of every GLP-1 drug and our overview of the best peptides for weight loss. If you’re weighing a pill instead, see orforglipron vs tirzepatide.
Who each may suit: questions for your clinician
- “I need to lose weight now.” Tirzepatide is approved and produced more weight loss in its trials.[5]
- “I have fatty liver disease with scarring.” Ask about current options and whether a clinical trial, such as LIVERAGE, is open to you.[11]
- “I have type 2 diabetes.” Mounjaro is approved for it; survodutide lowered HbA1c by about 0.8 to 0.9 points in SYNCHRONIZE-2.[9][2]
- “I couldn’t tolerate GLP-1 side effects.” Survodutide’s stomach side effects were frequent, so it may not be easier.[1]
The verdict
For weight loss, tirzepatide leads on the available evidence and is approved today. Survodutide may earn a place as a liver-focused option if phase 3 biopsy trials confirm its early results and it reaches approval. What isn’t known: how the two compare in the same people, survodutide’s long-term heart safety, and when, or whether, it will be filed with FDA. See also CagriSema vs Zepbound and retatrutide vs tirzepatide.
